(Q24248704)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12804394%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

review article

1 reference

title

Chlorpromazine versus placebo for schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12804394%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

0 references

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12804394%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

B Thornley

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12804394%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

G Awad

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12804394%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

C E Adams

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12804394%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

language of work or name

English

0 references

publication date

1 January 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12804394%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

4 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12804394%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

CD000284

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12804394%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12804394%20AND%20SRC:MED&resulttype=core&format=json

Molindone in chronic schizophrenia.

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Drug Treatment in Newly Admitted Schizophrenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Evaluation of Butaclamol in Chronic Schizophrenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Physician bias and the double-blind.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Importance of Psychiatric Diagnosis in Prediction of Clinical Drug Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

The immediate effects of chlorpromazine in newly admitted schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of nonrelapsed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Temporal Effects of Drug and Placebo in Delaying Relapse in Schizophrenic Outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Prophylactic effect of neuroleptics in symptom-free schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

A controlled clinical study of chlorpromazine and reserpine in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Phenothiazine Effects on Psychological and Psychophysiological Dysfunction in Chronic Schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Chlorpromazine in psychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Evaluation of tranquilizing drugs in the management of acute mental disturbance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Paradoxical reaction to L-dopa in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

THE USE OF ADJECTIVE CHECK LISTS WITH PSYCHOTIC PATIENTS: THE PROBLEM OF PSEUDO-RESPONSES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE ON SYSTOLIC BLOOD PRESSURE IN PSYCHIATRIC PATIENTS: RELATIONSHIPS TO AGE, DIAGNOSIS AND INITIAL BLOOD PRESSURE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Chlorpromazine-procyclidine and imipramine: effects on thyroid function in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

A Comparison between Chlorpromazine and Thiothixene in a Veterans Administration Hospital Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Thiothixene in young disturbed children. A pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Chlorpromazine and body image. Effects on chronic schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Clinical and work performance variables in phenothiazine therapy of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

High Doses of Trifluperazine and Tardive Dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

The Northwick Park Study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Short-term outcome in trial entrants and trial eligible patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Effects of chlorpromazine and lorazepam on explicit memory, repetition priming and cognitive skill learning in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Effect of two phenothiazine drugs on concentrative attention span of chronic schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Ritanserin as add-on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Chlorpromazine in the treatment of mental illness. III. The problem of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Effects of antipsychotic drugs on memory functions of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

A controlled trial of anti-Parkinson drugs in drug-induced Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Effect of chlorpromazine on the behavior of chronically overactive psychotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Comparative study of chlorpromazine and insulin coma in therapy of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Combined chlorpromazine and reserpine in the treatment of chronic psychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

The role of personality variables in response to chlorpromazine, dextroamphetamine and placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Treatment of hyperkinetic emotionally disturbed children with prolonged administration of chlorpromazine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Maintenance antipsychotic therapy: is the cure worse than the disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Persistent Phenothiazine Dyskinesia Treated with Tetrabenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Laterality, Attention and Rate Effects in the Auditory Temporal Discrimination of Chronic Schizophrenics: The Effect of Treatment with Chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Work performance versus clinical assessment in the evaluation of phenothiazine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Chlorpromazine and serial reaction performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Lateralization of emotional expression under a neuroleptic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Chlorpromazine and the lateralisation of the perception of emotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

A Controlled Outpatient Trial of Perphenazine-Amitriptyline and Chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Predictive value of pharmaco-electroencephalography in early human-pharmacological evaluations of psychoactive drugs. First example: savoxepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Pharmaco-EEG profile of maroxepine: third example to discuss the predictive value of pharmaco-electroencephalography in early human pharmacological evaluations of psychoactive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Chlorpromazine: direct measurement of differential behavioral effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

An Appraisal of the Continuing Practice of Prescribing Tranquillizing Drugs for Long-stay Psychiatric Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Mechanism of the antipsychotic effect in the treatment of acute schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Effects of Chlorpromazine and Trifluoperazine on the Activity of Chronic Schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

3-Methoxy-4-hydroxyphenylglycol excretion in acutely schizophrenic patients during a controlled clinical trial of the isomers of flupenthixol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Effect of prolonged chlorpromazine administration on the sleep of chronic schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Chlorpromazine; a major advance in psychiatric treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Clopenthixol: a controlled trial in chronic hospitalized schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Chlorpromazine and sleep in psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Relationship between plasma-levels of chlorpromazine and effects on EEG and evoked potentials in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Trial of Maintenance Therapy in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Effects of chlorpromazine and promazine on perseveration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Haloperidol and Chlorpromazine: A Double-Blind Cross-Over Trial and Clinical Study in Children and Adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Treatment of Acute Mental Disorders with an Adrenal Steroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Meprobamate and chlorpromazine in psychotherapy. Some effects on anxiety and hostility of outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Integrated EEG. variability: drug effects in acute schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Perceptual challenge to measure illness and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Suriclone enhances the actions of chlorpromazine on human psychomotor performance but not on memory or plasma prolactin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Chlorpromazine and chronic neurotic tension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Psychological response to chlorpromazine in a group of psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Prolactin hyperresponsiveness to D-fenfluramine in drug-free schizophrenic patients: a placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Bilateral skin conductance and the pupillary light-dark reflex: manipulation by chlorpromazine, haloperidol, scopolamine, and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Chlorpromazine (thorazine) for mental illness in the presence of pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

The effect of chlorpromazine on the return rate of 250 patients released from the Rochester State Hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

A trial of five tranquillizing drugs in psychoneurosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Are prophylactic antiparkinson drugs necessary? A controlled study of procyclidine withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Clinical evaluation of azacyclonol, chlorpromazine, and reserpine on a group of chronic psychotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Effects of mode of management on plasma chlorpromazine in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Trifluoperazine in the treatment of psychotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Chlorpromazine in Treatment of Elderly Psychotic Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Bioequivalency of generic and brand-named chlorpromazine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

TIME-SERIES, FREQUENCY ANALYSIS, AND ELECTROGENESIS OF THE EEGs OF NORMALS AND PSYCHOTICS BEFORE AND AFTER DRUGS

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Tranquilizers or Anti-Depressants for Chronic Schizophrenics: A Long Term Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

A comparison of fluphenazine and chlorpromazine on critical flicker fusion frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Biochemical versus psychopathological action profile of neuroleptics: A comparative study of chlorpromazine and oxypertine in acute psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Electrocardiographic changes in patients receiving neuroleptic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

The use of pericyazine and chlorpromazine with disturbed mentally subnormal patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

An appraisal of chlorpromazine; general principles for administration of chlorpromazine, based on experience with 1,090 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Propranolol as an adjunct to the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Use of chlorpromazine and reserpine in the treatment of emotional disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Transnational stability of gender differences in schizophrenia? An analysis based on the WHO study on determinants of outcome of severe mental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Enlargement of cerebral third ventricle in psychotic patients with delayed response to neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Gender and schizophrenia. Results of an epidemiologically-based family study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Chemical brain anatomy in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Content and quality of 2000 controlled trials in schizophrenia over 50 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Antipsychotic drug use in the United States, 1976-1985.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

Symptomatic Response to Antipsychotics Differs between Recent Onset and Recurrent Chronic Schizophrenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

A comparison of chlorpromazine and reserpine in chronic psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Effects of chlorpromazine on chronic lobotomized schizophrenic patients; a controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Comparison of psychological effects of certain centrally acting drugs in man.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Relationships between effects of a number of centrally acting drugs and personality

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Chlorpromazine and communication processes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Chlorpromazine used with an intensive occupational therapy program; a controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Denial of illness in schizophrenic out-patients: effects of psychopharmacological treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Drug therapy in schizophrenia. A controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital, and placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

EEG AND BEHAVIORAL CHANGES IN SCHIZOPHRENIA

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

PHENOTHIAZINES IN PREVENTION OF PSYCHIATRIC HOSPITALIZATION. 3. DELAY OR PREVENTION OF HOSPITALIZATION

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

LONG-TERM FOLLOW-UP STUDY OF SCHIZOPHRENIC PATIENTS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization--a reevaluation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Competing voice messages. Effects of message load and drugs on the ability of acute schizophrenics to attend

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Family interaction patterns, drug treatment, and change in social aggression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Prediction of response to phenothiazines in schizophrenia. A crossvalidation study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Premorbid Asocial Adjustment and Response to Phenothiazine Treatment Among Schizophrenic Inpatients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Effect of antiparkinsonian medication on plasma levels of chlorpromazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Intermittent vs maintenance medication in schizophrenia. Two-year results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Randomized controlled trials in Archives of General Psychiatry (1959-1995): a prevalence study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Treatment of psychotic states with chlorpromazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Prevention of psychiatric hospitalization with use of psychopharmacological agents

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

PHENOTHIAZINES IN PREVENTION OF PSYCHIATRIC HOSPITALIZATION. II. DURATION OF TREATMENT EXPOSURE

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Effects of chronic chlorpromazine administration on systemic arterial pressure in schizophrenic patients: Relationship of body position to blood pressure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A comparison of the behavioral effects of periodic administration of chlorpromazine and a “sustained-release” form of chlorpromazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Comparison of thioridazine and chlorpromazine in doctor's choice research design

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Viloxazine and the depressed schizophrenic--methodological issues

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Effect of minor and major tranquilizers on somatosensory evoked potentials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The effects of chlorpromazine and secobarbital under two conditions of reinforcement on the performance of chronic schizophrenic subjects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

An exploration of the autonomic effects of phenothiazines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Evaluation of trifluperidol in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Clinical efficacy of chlorpromazine-procyclidine combination, imipramine and placebo in depressive disorders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Psychiatric diagnosis and a typology of clinical drug effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Chlorpromazine in chronic schizophrenia: behavioral dose-response relationships

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The effects of long term administration of psychotrophic drugs on human sleep. IV. The effects of chlorpromazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

[Effects of various drugs on flicker fusion frequency. II. Phenothiazine derivatives (with reference to the dependence of the results on the chronological course of experiments]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Chlorpromazine in chronic schizophrenic women: I. Experimental design and effects at maximum point of treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Comparison of low and high dosage procedures in chlorpromazine therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Treatment of schizophrenic disorder, paranoid type, with intramuscular recombinant alpha-2b interferon

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The effect of antipyretic analgesics on the metabolism of chlorpromazine in man

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Work study in the assessment of the effects of phenothiazines in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

DISCONTINUATION OR REDUCTION OF CHEMOTHERAPY IN CHRONIC SCHIZOPHRENICS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The evaluation of chlorpromazine therapy in chronic schizophrenic women. A replicated experiment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The influence of chlorpromazine and amylobarbitone on the recovery limb of the electrodermal response

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Short-lived effect of (Des-Tyr)-gamma-endorphin in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The clinical relevance of an auditory attention task (PAT) in a longitudinal study of chronic schizophrenia, with placebo substitution for chlorpromazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia. A two year longitudinal study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A comparative study of butaperazine, chlorpromazine and placebo in chronic schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Double-blind trial of fluphenazine decanoate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Second-generation antipsychotics in the emergency care setting. A prospective naturalistic study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Immediate effects of chlorpromazine and perphenazine following neuroleptic washout on word association of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

COMMUNICATION OF BODY COMPLAINTS AND PARANOID SYMPTOM CHANGE UNDER CONDITIONS OF PHENOTHIAZINE TREATMENT

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Effects of chlorpromazine on primary-process thought manifestations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The short-term effects of chlorpromazine on psychiatric patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The effects of thorazine on learning and retention in schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Stylus maze performance of chronic schizophrenics taking chlorpromazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A comparison of the effects of phenobarbital, promethazine, chlorpromazine, and placebo upon mental hospital patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The effects of chlorpromazine on learning in chronic psychotics.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Platelet monoamine oxidase in schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Subjective response to neuroleptics in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Subjective response to antipsychotic drugs: failure to replicate predictions of outcome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Studies on mescaline. VI. Therapeutic aspects of the mescaline-chlorpromazine combination.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A comparative study of the effect on anxiety of chlorpromazine, reserpine, phenobarbital, and a placebo.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The use of chlorpromazine in psychotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A comparative study of chlorpromazine and triflupromazine in the management of the chronic hospitalized psychotic patient.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Chlorpromazine in schizophrenic withdrawal and in the withdrawn schizophrenic

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The psychiatric physician and the phenothiazine tranquilizers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The effect of chlorpromazine on the variability of motor task performance in schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Effects of chlorpromazine on behavior in emotionally disturbed children.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The effects of imipramine and chlorpromazine on perceptual analytic ability, perceptual responsivity and memory as revealed in Rorschach responses.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Clinical judgment in the assessment of psychopharmacological effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

On the modification of paranoid symptomatology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The effects of carphenazine, trifluoperazine and chlorpromazine on ward behavior, physiological functioning and psychological test scores in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Attention to competing voice messages by nonacute schizophrenic patients. Effects of message load, drugs, dosage levels and patient background

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The hospitalization proneness scale as a predictor of response to phenothiazine treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Predicting response to phenothiazines: the right drug for the right patient

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The effects of chlorpromazine and methamphetamine on visual signal-from-noise detection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

On the modification of paranoid symptomatology. II. Stylistic considerations and the effectiveness of phenothiazines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Research design for analyzing drug-environment-behavior interactions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Self-administration of medication by psychiatric inpatients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Therapeutic reversal with benxtropine in schizophrenics. Practical and theoretical significance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

High Potency Neuroleptics and Violence in Schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Chlorpromazine in Chronic Schizophrenic Women: Rate of Onset and Rate of Dissipation of Drug Effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Chlorpromazine in Women with Chronic Schizophrenia: The Effect on Cholesterol Levels and Cholesterol-Behavior Relationships

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A comparison of oxypertine and chlorpromazine in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Antipsychotics in the elderly

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Psychomotor impairment and cognitive disturbances induced by neuroleptics.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Confrontation vs. belief modification in persistently deluded patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Treatment and outcome of anorexia nervosa

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Influence of selection of patients on results of clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Consistency and similarity of drug-EEG responses in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The EEG Effects of Chemically and Clinically Dissimilar Antipsychotics — Molindone vs. Chlorpromazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Are There Schizophrenics for Whom Drugs May be Unnecessary or Contraindicated?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Psychotropic drug prescription pattern in a developing country (Nigeria). The need for an essential psychotherapeutic drug list.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Clinical investigation of chlorpromazine and reserpine in private psychiatric practice

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Chlorpromazine: alone and as an adjunct to group psychotherapy in the treatment of psychiatric patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Clinical evaluation of two phenothiazine compounds promazine and mepazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A controlled clinical psychiatric study of the drug chlorpromazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The ataractic drugs: the present position of chlorpromazine, frenquel, pacatal, and reserpine in the psychiatric hospital

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A controlled study of the short-term differential treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Perphenazine-a drug modifying consciousness

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Comparison of proclorperazine and chlorpromazine in hospitalized chronic schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Pre-admission drug treatment of state psychiatric hospital patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A comparison of triflupromazine (vesprin), chlorpromazine and placebo in 85 chronic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Termination of chlorpromazine with schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Specific behavioral changes produced by chlorpromazine in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Responses of treatment-refractory chronic schizophrenics to chlorpromazine with concurrent adrenocortical steroid

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A long term evaluation of chlorpromazine in six chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro-amphetamine, imipiramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A comparison of the effectiveness of trifluoperazine and chlorpromazine in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The relationship between serotonin antagonism and tranquilizing activity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

PHENOTHIAZINE EXCRETION IN CHRONIC SCHIZOPHRENICS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

ARE TRANQUILIZER COMBINATIONS MORE EFFECTIVE THAN A SINGLE TRANQUILIZER?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Follow-up study of formerly hospitalized voluntary psychiatric patients: the first two years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Evaluation of treatment with recorded interviews

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Phenothiazine Derivatives and Morphologic Changes in the Liver

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The effect of chlorpromazine on the swallowing function in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Persistence of Neurological Symptoms Due to Neuroleptic Drugs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Platelet monoamine oxidase activity in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Course of treatment response in first-episode and chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The effect of chlorpromazine and benzhexol on memory and psychomotor function in healthy volunteers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Chlorpromazine, trifluoperazine and placebo with long-term mental hospital patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

[Comparative study of fluphenazine ethanate, fluphenazine bichlorhydrate and placebos in chronic schizophrenics]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Megavitamin Treatment of Schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Relationship of adverse drug reactions to length of hospital-stay in genetically subgrouped schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Chlorpromazine in the treatment of the chronic disturbed schizophrenic patient

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A research method to assess a new tranquilizing drug

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Combined treatment with chlorpromazine and reserpine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Ritalin and chlorpromazine in chronic schizophrenia: a controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A double-blind controlled comparison of the effects of chlorpromazine, barbiturate and a placebo in 142 chronic psychotic in-patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A controlled study of the prognostic significance of autonomic responses in the chlorpromazine treatment of disturbed psychotic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Investigation of a new compound, B.W.203, and of chlorpromazine in the treatment of psychosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Psychological effects of centrally acting drugs in man; effects of chlorpromazine secobarbital on visual and motor behaviour

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A comparison of the psychological effects of acute and chronic administration of chlorpromazine and secobarbital (quinalbarbitone) in schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The relative efficacy of vespral and chlorpromazine in the treatment of a group of chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Clinical trial of promazine hydrochloride and acetylpromazine in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A controlled comparative investigation of the effects of promazine, chlorpromazine, and a placebo in chronic psychosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A controlled trial of ethylcrotonylurea

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A comparative controlled trial of methortrimeprazine ("veractil") in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

The effect of chlorpromazine on the incidence of epileptic phenomena during insulin coma therapy. A statistical investigation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A controlled trial of thiopropazate dihydrochloride (dartalan). chlorpromazine and occupational therapy in chronic schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Chlorpromazine and Pecazine in Chronic Schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A clinical trial of largactil (chlorpromazine), stemetil (prochlorperazine) and veractil (methotrimeprazine)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A double-blind trial to investigate the effects of Thorazine (Largactil, chlorpromazine), Compazine (Stemetil, prochlorperazine) and Stelazine (trifluoperazine) in paranoid schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

CHANGES IN SCHIZOPHRENIC PSYCHOPATHOLOGY AND WARD BEHAVIOUR AS A FUNCTION OF PHENOTHIAZINE TREATMENT

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Chlorpromazine and the untreated chronic schizophrenic: a long-term trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Drugs and motor activity in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Phenothiazine withdrawal in schizophrenics in a hostel

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Propranolol in schizophrenia. I. Comparison of propranolol, chlorpromazine and placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

A randomised controlled trial of prophylactic neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Post-mortem antipsychotic drug concentrations and unexplained deaths

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Early intervention in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

EFFECT OF PHENOTHIAZINES ON THE THINKING OF ACUTE SCHIZOPHRENICS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. The Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000284

7 January 2021

10.1002/14651858.CD000284

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12804394%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

26 June 2017

1 reference